Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous Bevacizumab in Relapsed/Progressive Glioblastoma
NCT02157103Phase 2Completed
- Sponsor
- Emory University
- Start
- Jan 2014
- Primary completion
- Nov 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in glioblastoma (GBM), sponsored by Emory University. Started Jan 2014; status: completed.
02
Drugs
bevacizumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02157103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02157103.